Hanson & Doremus Investment Management’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.21M Sell
56,094
-2,834
-5% -$332K 0.73% 23
2026
Q1
$7.09M Buy
58,928
+337
+0.6% +$38.9K 0.82% 21
2025
Q4
$6.17M Sell
58,591
-10,871
-16% -$1.02M 0.74% 24
2025
Q3
$5.83M Sell
69,462
-16,277
-19% -$1.34M 0.73% 24
2025
Q2
$6.79M Buy
85,739
+24,228
+39% +$1.93M 0.91% 19
2025
Q1
$5.52M Buy
61,511
+7,760
+14% +$725K 0.81% 20
2024
Q4
$5.35M Buy
53,751
+1,382
+3% +$142K 0.84% 21
2024
Q3
$5.95M Sell
52,369
-1,666
-3% -$198K 0.94% 17
2024
Q2
$6.69M Buy
54,035
+368
+0.7% +$47.4K 1.12% 15
2024
Q1
$7.08M Buy
53,667
+236
+0.4% +$29.1K 1.22% 15
2023
Q4
$5.83M Buy
53,431
+1,927
+4% +$200K 1.1% 15
2023
Q3
$5.3M Sell
51,504
-36
-0.1% -$3.88K 1.09% 16
2023
Q2
$5.95M Buy
51,540
+1,273
+3% +$145K 1.24% 13
2023
Q1
$5.35M Sell
50,267
-7,757
-13% -$837K 1.19% 12
2022
Q4
$6.44M Buy
58,024
+8,260
+17% +$844K 1.39% 11
2022
Q3
$4.29M Buy
49,764
+2,397
+5% +$214K 1.11% 14
2022
Q2
$4.32M Buy
47,367
+1,473
+3% +$131K 1.06% 15
2022
Q1
$3.77M Buy
45,894
+1,061
+2% +$83.7K 0.81% 22
2021
Q4
$3.44M Buy
44,833
+2,358
+6% +$188K 0.74% 25
2021
Q3
$3.19M Buy
42,475
+16,415
+63% +$1.25M 0.74% 24
2021
Q2
$2.16M Sell
26,060
-13,259
-34% -$986K 0.65% 27
2021
Q1
$2.89M Buy
39,319
+3,148
+9% +$232K 0.67% 26
2020
Q4
$2.82M Buy
36,171
+8,860
+32% +$678K 0.7% 24
2020
Q3
$2.16M Buy
27,311
+496
+2% +$38.9K 0.65% 27
2020
Q2
$1.98M Sell
26,815
-8,968
-25% -$675K 0.63% 29
2020
Q1
$2.63M Buy
35,783
+7,138
+25% +$561K 0.89% 22
2019
Q4
$2.49M Buy
28,645
+944
+3% +$77.5K 0.71% 29
2019
Q3
$2.23M Sell
27,701
-560
-2% -$44.9K 0.69% 30
2019
Q2
$2.26M Sell
28,261
-1,820
-6% -$139K 0.72% 30
2019
Q1
$2.39M Sell
30,081
-31
-0.1% -$2.32K 0.79% 30
2018
Q4
$2.2M Sell
30,112
-1,118
-4% -$78.9K 0.79% 29
2018
Q3
$2.11M Buy
31,230
+982
+3% +$62.6K 0.66% 37
2018
Q2
$1.75M Sell
30,248
-6,897
-19% -$389K 0.58% 46
2018
Q1
$1.93M Buy
37,145
+7,206
+24% +$389K 0.6% 42
2017
Q4
$1.61M Buy
29,939
+155
+0.5% +$8.59K 0.54% 49
2017
Q3
$1.82M Buy
29,784
+1,248
+4% +$75.7K 0.64% 38
2017
Q2
$1.75M Sell
28,536
-454
-2% -$27.6K 0.64% 39
2017
Q1
$1.76M Buy
28,990
+84
+0.3% +$5.1K 0.7% 36
2016
Q4
$1.62M Sell
28,906
-330
-1% -$19.3K 0.7% 37
2016
Q3
$1.74M Sell
29,236
-414
-1% -$24.2K 0.81% 32
2016
Q2
$1.63M Buy
29,650
+683
+2% +$36.4K 0.74% 34
2016
Q1
$1.46M Sell
28,967
-26
-0.1% -$1.27K 0.66% 40
2015
Q4
$1.46M Buy
28,993
+251
+0.9% +$12.7K 0.66% 42
2015
Q3
$1.35M Buy
28,742
+1,281
+5% +$68K 0.65% 43
2015
Q2
$1.49M Buy
27,461
+3,590
+15% +$201K 0.64% 46
2015
Q1
$1.31M Sell
23,871
-115
-0.5% -$6.51K 0.55% 53
2014
Q4
$1.3M Buy
23,986
+399
+2% +$22.2K 0.56% 53
2014
Q3
$1.33M Sell
23,587
-363
-2% -$20.4K 0.6% 50
2014
Q2
$1.32M Buy
23,950
+52
+0.2% +$2.84K 0.61% 52
2014
Q1
$1.29M Buy
23,898
+85
+0.4% +$4.4K 0.61% 50
2013
Q4
$1.14M Sell
23,813
-179
-0.7% -$8.18K 0.55% 56
2013
Q3
$1.09M Buy
23,992
+484
+2% +$22.1K 0.55% 57
2013
Q2
$1.04M Buy
+23,508
New +$1.05M 0.57% 55

Other funds holding MRK

Hanson & Doremus Investment Management's MRK Position: Q2 2026 in Review

Hanson & Doremus Investment Management reduced its Merck (MRK) stake by 4.8% in Q2 2026, selling an estimated $332K and leaving 56,094 shares worth $7.21M. The position accounts for 0.73% of the portfolio, ranked #23.

Hanson & Doremus Investment Management first reported a position in MRK in Q2 2013 and has held it in 53 quarters since. 3,819 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Hanson & Doremus Investment Management held 56,094 shares of Merck worth $7.21M as of Q2 2026.
  • Hanson & Doremus Investment Management sold 2,834 Merck shares in Q2 2026, an estimated $332K.
  • Merck made up 0.73% of Hanson & Doremus Investment Management's portfolio in Q2 2026, its #23 holding.
  • Hanson & Doremus Investment Management first reported a position in Merck in Q2 2013 and has held it in 53 quarters since.
  • 3,819 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Hanson & Doremus Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.